Molecular classification and clonal differentiation of hepatocellular carcinoma: The step forward for patient selection for liver transplantation

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 4, 2011, Pages 539-552

  Gehrau, Ricardo ^a   Mas, Valeria ^a,b   Archer, Kellie J ^b   Maluf, Daniel ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

biomarkers; criteria; gene expression; genetics; genomics; hepatocellular carcinoma; microarray; multicentricity

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB;

ALLELIC IMBALANCE; ARTIFICIAL NEURAL NETWORK; CANCER CLASSIFICATION; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLASSIFICATION ALGORITHM; CLONAL VARIATION; COMPUTER ANALYSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENOME ANALYSIS; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; LIVER TRANSPLANTATION; MOLECULAR DIAGNOSIS; PATIENT SELECTION; REFERENCE VALUE; REVIEW; RNA ISOLATION; TREATMENT INDICATION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 79960820259     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.48     Document Type: Review

References (78)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27(9), 1485-1491 (2009).
3. Centers for Disease Control and Prevention (CDC).Hepatocellular carcinoma - United States, 2001-2006. MMWR Morb. Mortal. Wkly. Rep. 59(17), 517-520 (2010).
4. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45(4), 529-538 (2006). (Pubitemid 44307383)
5. Jain S, Singhal S, Lee P, Xu R. Molecular genetics of hepatocellular neoplasia. Am. J. Transl. Res. 2(1), 105-118 (2010).
6. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 9(2), 191-211 (2005).
7. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7), 2557-2576 (2007). (Pubitemid 46890874)
8. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 36(1), 227-242 (2002). (Pubitemid 34700782)
9. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334(11), 693-699 (1996). (Pubitemid 26079803)
10. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33(6), 1394-1403 (2001). (Pubitemid 32496976)
11. Llovet JM, Schwartz M, Fuster J, Bruix J. Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. Semin. Liver Dis. 26(3), 248-253 (2006). (Pubitemid 44141932)
12. Freeman RB, Mithoefer A, Ruthazer R et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl. 12(10), 1504-1511 (2006). (Pubitemid 44594281)
13. Hanna RF, Kased N, Kwan SW et al. Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. Am. J. Roentgenol. 190(1), 47-57 (2008).
14. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 25(27), 3848-3856 (2006). (Pubitemid 43980480)
15. Washburn K. Model for End Stage Liver Disease and hepatocellular carcinoma: a moving target. Transplant. Rev. (Orlando).24(1), 11-17 (2010).
16. Ishizaki Y, Kawasaki S. The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future).J. Gastroenterol. 43(1), 18-26 (2008). (Pubitemid 351324981)
17. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am. J. Transplant. 7(11), 2587-2596 (2007). (Pubitemid 47561609)
18. Yao FY. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Hepatol. Res. 37(Suppl. 2), S267-S274 (2007).
19. Duffy JP, Vardanian A, Benjamin E et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann. Surg. 246(3), 502-509; discussion 509-5011 (2007). (Pubitemid 47312148)
20. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 10(1), 35-43 (2009).
21. Raj A, McCall J, Gane E. Validation of the 'Metroticket' predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma. J. Hepatol. DOI: 10.1016/j.jhep.2011.01.052 (2011) (Epub ahead of print).
22. Decaens T, Roudot-Thoraval F, Hadni- Bresson S et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl. 12(12), 1761-1769 (2006). (Pubitemid 44911801)
23. Ju MK, Choi GH, Huh KH et al. UCSF criteria by pre-transplant radiologic study can not assure similar post-transplant results of hepatocellular carcinoma within Milan criteria. Hepatogastroenterology 57(101), 819-825 (2010).
24. Toso C, Trotter J, Wei A et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 14(8), 1107-1115 (2008).
25. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 49(3), 832-838 (2009).
26. Macaron C, Hanouneh IA, Lopez R, Aucejo F, Zein NN. Total tumor volume predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria. Transplant. Proc. 42(10), 4585-4592 (2010).
27. Lu CH, Chen CL, Cheng YF et al. Correlation between imaging and pathologic findings in explanted livers of hepatocellular carcinoma cases. Transplant. Proc. 42(3), 830-833 (2010).
28. Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. Expert Rev. Anticancer Ther. 10(4), 507-519 (2010).
29. Yu NC, Chaudhari V, Raman SS et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 9(2), 161-167 (2011).
30. Schmitt TM, Kumer SC, Shah N, Argo CK, Northup PG. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions. Ann. Hepatol. 9(4), 390-396 (2010).
31. Iavarone M, Sangiovanni A, Forzenigo LV et al. Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. Hepatology 52(5), 1723-1730 (2010).
32. Colecchia A, Montrone L, Scaioli E, Festi D. Percutaneous liver biopsy in the clinical management of hepatocellular carcinoma: back to the future. Hepatology (2010).
33. Cillo U, Vitale A, Bassanello M et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann. Surg. 239(2), 150-159 (2004). (Pubitemid 38176347)
34. Cillo U, Vitale A, Grigoletto F et al. Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. Am. J. Transplant. 7(4), 972-981 (2007). (Pubitemid 46481197)
35. Vakili K, Pomposelli JJ, Cheah YL et al. Living donor liver transplantation for hepatocellular carcinoma: increased recurrence but improved survival. Liver Transpl. 15(12), 1861-1866 (2009).
36. Dudek K, Kornasiewicz O, Remiszewski P et al. Impact of tumor characteristic on the outcome of liver transplantation in patients with hepatocellular carcinoma. Transplant. Proc. 41(8), 3135-3137 (2009).
37. Marshall AE, Rushbrook SM, Vowler SL et al. Tumor recurrence following liver transplantation for hepatocellular carcinoma: role of tumor proliferation status. Liver Transpl. 16(3), 279-288 (2010).
38. Lai Q, Merli M, Ginanni Corradini S et al. Predictive factors of recurrence of hepatocellular carcinoma after liver transplantation: a multivariate analysis. Transplant. Proc. 41(4), 1306-1309 (2009).
39. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 53(3), 1020-1022 (2011).
40. International Consensus Group for Hepatocellular Neoplasia. The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49(2), 658-664 (2009).
41. Cucchetti A, Piscaglia F, Grigioni AD et al. Preoperative prediction of hepatocellular carcinoma tumor grade and micro-vascular invasion by means of artificial neural network: a pilot study. J. Hepatol. 52(6), 880-888 (2010).
42. Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W, Choti MA. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann. Surg. 245(3), 435-442 (2007). (Pubitemid 46673140)
43. Morimoto O, Nagano H, Sakon M et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J. Hepatol. 39(2), 215-221 (2003). (Pubitemid 36920557)
44. Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T, Mori M. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J. Gastroenterol. 45(2), 146-152 (2010).
45. Roncalli M, Park YN, Di Tommaso L. Histopathological classification of hepatocellular carcinoma. Dig. Liver Dis. 42(Suppl. 3), S228- S234 (2010).
46. Miyagawa S, Kawasaki S, Makuuchi M. Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C. Hepatology 24(2), 307-310 (1996). (Pubitemid 26260024)
47. van der Sijp JR, van Meerbeeck JP, Maat AP et al. Determination of the molecular relationship between multiple tumors within one patient is of clinical importance. J. Clin. Oncol. 20(4), 1105-1114 (2002). (Pubitemid 34141856)
48. Chen YJ, Yeh SH, Chen JT et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 119(2), 431-440 (2000).
49. Ng IO, Guan XY, Poon RT, Fan ST, Lee JM. Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J. Pathol. 199(3), 345-353 (2003). (Pubitemid 36266857)
50. Finkelstein SD, Marsh W, Demetris AJ et al. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology 37(4), 871-879 (2003). (Pubitemid 36397398)
51. Lin YW, Lee HS, Chen CH, Huang GT, Lee PH, Sheu JC. Clonality analysis of multiple hepatocellular carcinomas by loss of heterozygosity pattern determined by chromosomes 16q and 13q. J. Gastroenterol. Hepatol. 20(4), 536-546 (2005).
52. Li Q, Wang J, Juzi JT et al. Clonality analysis for multicentric origin and intrahepatic metastasis in ecurrent and primary hepatocellular carcinoma. J. Gastrointest. Surg. 12(9), 1540-1547 (2008).
53. Taniguchi K, Yamada T, Sasaki Y, Kato K. Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma. BMC Cancer 10, 530 (2010).
54. Wong QW, Wong N, Lai PB, To KF, Wong N. Clonal relationship of tumor nodules in hepatocellular carcinoma: a hierarchical clustering analysis of comparative genomic hybridization data. Hum. Pathol. 36(8), 893-898 (2005). (Pubitemid 41187908)
55. Wu JC, Sun BS, Ren N, Ye QH, Qin LX. Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH. J. Cancer Res. Clin. Oncol. 136(4), 595-601 (2010).
56. Wong CM, Lee JM, Lau TC, Fan ST, Ng IO. Clinicopathological significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma. Clin. Cancer Res. 8(7), 2266-2272 (2002). (Pubitemid 34753600)
57. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin. Liver Dis. 30(1), 3-16 (2010).
58. Nomoto S, Kinoshita T, Kato K et al. Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br. J. Cancer 97(9), 1260-1265 (2007). (Pubitemid 350035807)
59. Sawyers CL. The cancer biomarker problem. Nature 452(7187), 548-552 (2008). (Pubitemid 351483368)
60. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452(7187), 564-570 (2008). (Pubitemid 351483370)
61. Kim K, Zakharkin SO, Allison DB. Expectations, validity, and reality in gene expression profiling. J. Clin. Epidemiol. 63(9), 950-959 (2010).
62. Imbeaud S, Ladeiro Y, Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin. Liver Dis. 30(1), 75-86 (2010).
63. Yu GR, Kim SH, Park SH et al. Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma. Exp. Mol. Med. 39(5), 641-652 (2007).
64. Mas VR, Maluf DG, Archer KJ et al. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol. Med. 15(3-4), 85-94 (2009).
65. Boyault S, Rickman DS, de Reynies A et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45(1), 42-52 (2007). (Pubitemid 46144363)
66. Chiang DY, Villanueva A, Hoshida Y et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 68(16), 6779-6788 (2008).
67. Hoshida Y, Nijman SM, Kobayashi M et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69(18), 7385-7392 (2009).
68. Toffanin S, Hoshida Y, Lachenmayer A et al. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011).
69. Villanueva A, Hoshida Y, Battiston C et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140(5), 1501-1512.e2 (2011).
70. Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359(19), 1995-2004 (2008).
71. Mas VR, Maluf DG, Dumur CI et al. Molecular techniques for identifying HCC origin and biology after orthotopic liver transplantation. Diagn. Mol. Pathol. 15(2), 90-94 (2006). (Pubitemid 44350485)
72. Mas VR, Fisher RA, Archer KJ et al. Genes associated with progression and recurrence of hepatocellular carcinoma in hepatitis C patients waiting and undergoing liver transplantation: preliminary results. Transplantation 83(7), 973-981 (2007). (Pubitemid 46682740)
73. Nakata T, Seki N, Miwa S et al. Identification of genes associated with multiple nodules in hepatocellular carcinoma using cDNA microarray: multicentric occurrence or intrahepatic metastasis? Hepatogastroenterology 55(84), 865-872 (2008). (Pubitemid 351975943)
74. Kennedy RE, Kerns RT, Kong X, Archer KJ, Miles MF. SScore: an R package for detecting differential gene expression without gene expression summaries. Bioinformatics 22(10), 1272-1274 (2006). (Pubitemid 43779022)
75. Shi L, Perkins RG, Fang H, Tong W. Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential. Curr. Opin. Biotechnol. 19(1), 10-18 (2008).
76. Bammler T, Beyer RP, Bhattacharya S et al. Standardizing global gene expression analysis between laboratories and across platforms. Nat. Methods 2(5), 351-356 (2005).
77. Irizarry RA, Warren D, Spencer F et al. Multiple-laboratory comparison of microarray platforms. Nat. Methods 2(5), 345-350 (2005).
78. Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J. Independence and reproducibility across microarray platforms. Nat. Methods 2(5), 337-344 (2005).